U.S. NIH Turbo Charges India’s COVID-19 Vaccine

An adjuvant developed with funding from the National Institutes of Health (NIH) has contributed to the success of the Covaxin COVID-19 vaccine, which roughly 25 million people have already received in India and elsewhere.Adjuvants are substances formulated as part of a vaccine to boost immune responses and enhance a vaccine’s effectiveness. Covaxin was developed and is manufactured in India by Bharat Biotech, stated the NIH on June 29, 2021.
Anthony S. Fauci, director of the National Institute of Allergy and Infectious Diseases (NIAID), said in a released press statement, “I am pleased that a novel vaccine adjuvant developed in the United States with NIAID support is part of an efficacious COVID-19 vaccine available to people in India.”